Indenture Agreements in the Pharmaceuticals Industry

638 Contracts & Agreements

Browse by Company

Acreage Holdings, Inc. (1 contract)
Aegerion Pharmaceuticals, Inc. (2)
AERIE PHARMACEUTICALS INC (2)
Akorn (1)
ALDER BIOPHARMACEUTICALS INC (3)
Alexza Pharmaceuticals Inc. (2)
Allergan, plc (18)
Amag Pharmaceuticals (8)
Amneal Pharmaceuticals, Inc. (6)
Amphastar Pharma (1)
AMYLIN PHARMACEUTICALS INC (4)
Anacor Pharmaceuticals, Inc. (3)
ANGIOTECH PHARMACEUTICALS INC (1)
ANI Pharma Inc (5)
Aquestive Therapeutics, Inc. (4)
ARADIGM CORP (2)
ARIAD PHARMACEUTICALS INC (2)
Assertio Holdings, Inc. (3)
Assertio Therapeutics, Inc (4)
AUXILIUM PHARMACEUTICALS INC (4)
AVADEL PHARMACEUTICALS PLC (4)
AVALON PHARMACEUTICALS INC (1)
AXYS PHARMACEUTICALS INC (4)
Bausch Health Companies Inc. (100)
Blue Water Acquisition Corp. (2)
BRADLEY PHARMACEUTICALS INC (2)
Bristol-Myers Squibb (15)
Canopy Growth Corp (4)
Catalent Inc (6)
CELGENE CORP (16)
CLS Holdings USA, Inc. (8)
COLLEGIUM PHARMACEUTICAL, INC (3)
Columbia Care Inc. (4)
CUBIST PHARMACEUTICALS INC (5)
DURA PHARMACEUTICALS INC (1)
DURECT CORP (1)
Egalet Corp (2)
Elanco Animal Health Inc (1)
ELITE PHARMACEUTICALS INC (1)
ENCYSIVE PHARMACEUTICALS INC (3)
Endo International plc (73)
Endo Pharmaceuticals Solutions Inc. (4)
EPIX Pharmaceuticals, Inc. (2)
GUILFORD PHARMACEUTICALS INC (1)
HARROW HEALTH, INC. (3)
HARVEST HEALTH & RECREATION INC. (1)
Horizon Pharma plc (19)
Innoviva, Inc. (6)
IntelGenx Technologies Corp. (4)
Iterum Therapeutics plc (2)
Jazz Pharmaceuticals plc (6)
Johnson & Johnson (2)
Jushi Holdings Inc. (1)
KEMPHARM, INC (1)
KING PHARMACEUTICALS INC (1)
Lannett Company, Inc. (1)
Lilly (Eli) & Co. (14)
Mallinckrodt (7)
Medicine Man Technologies, Inc. (1)
Merck (16)
MILLENNIUM PHARMACEUTICALS INC (5)
Molecular Insight Pharmaceuticals, Inc. (1)
Mylan N.V. (25)
NEKTAR THERAPEUTICS (6)
NEW RIVER PHARMACEUTICALS INC (1)
NPS PHARMACEUTICALS INC (7)
OMEROS CORP (5)
ONYX PHARMACEUTICALS INC (3)
Organon & Co. (8)
OSCIENT PHARMACEUTICALS CORP (2)
OSI PHARMACEUTICALS INC (3)
Pacira Pharmaceuticals, Inc. (6)
Paratek Pharmaceuticals, Inc. (2)
Perrigo (7)
Pfizer (25)
Phibro Animal Health Corporation (13)
Prestige Brands Holdings Inc (8)
Revance Therapeutics, Inc. (2)
Royalty Pharma plc (6)
SALIX PHARMACEUTICALS LTD (7)
SAVIENT PHARMACEUTICALS INC (2)
Sucampo Pharmaceuticals, Inc. (2)
Supernus Pharmaceuticals, Inc. (3)
SYNERGY PHARMACEUTICALS, INC. (2)
TETRALOGIC PHARMACEUTICALS CORP (1)
TEVA PHARMACEUTICAL INDUSTRIES LTD (14)
The Medicines Company (7)
Theravance Biopharma, Inc. (3)
Tilray, Inc. (8)
Trulieve Cannabis Corp. (1)
Upjohn Inc (11)
VALEANT PHARMACEUTICALS INTERNATIONAL (3)
VION PHARMACEUTICALS INC (1)
VIVUS INC (3)
XERIS PHARMACEUTICALS INC (2)
Zoetis (7)
ZOGENIX, INC. (2)

Recent Contracts

Category

Company

Industry

Jur. Jurisdiction

Filed

First Supplemental Senior Indenture for 5.750% Senior Notes due 2030 among Teva Pharmaceutical Finance Netherlands IV B.V., Teva Pharmaceutical Industries Limited, and The Bank of...

Indenture Agreements

TEVA PHARMACEUTICAL INDUSTRIES LTD

Pharmaceuticals

2025

Senior Indenture among Teva Pharmaceutical Finance Netherlands IV B.V., Teva Pharmaceutical Industries Limited, and The Bank of New York Mellon, dated May 28, 2025

Indenture Agreements

TEVA PHARMACEUTICAL INDUSTRIES LTD

Pharmaceuticals

2025

Fifth Supplemental Senior Indenture for 6.000% Senior Notes due 2032 among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited, and The Bank...

Indenture Agreements

TEVA PHARMACEUTICAL INDUSTRIES LTD

Pharmaceuticals

2025

Fifth Supplemental Senior Indenture for 4.125% Senior Notes due 2031 among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited, and The Bank of...

Indenture Agreements

TEVA PHARMACEUTICAL INDUSTRIES LTD

Pharmaceuticals

2025

First Supplemental Indenture to Indenture Dated May 19, 2025 among Pfizer Netherlands International Finance B.V., Pfizer Inc., and The Bank of New York Mellon

Indenture Agreements

Pfizer

Pharmaceuticals

2025

Indenture Agreement among Pfizer Netherlands International Finance B.V., Pfizer Inc., and The Bank of New York Mellon (May 19, 2025)

Indenture Agreements

Pfizer

Pharmaceuticals

2025

Second Supplemental Indenture for 9.50% Convertible Senior Notes due 2029 between Omeros Corporation and Computershare Trust Company, N.A.

Indenture Agreements

OMEROS CORP

Pharmaceuticals

2025

Second Supplemental Indenture for 9.50% Convertible Senior Notes due 2029 between Omeros Corporation and Computershare Trust Company, N.A.

Indenture Agreements

OMEROS CORP

Pharmaceuticals

2025

Eighth Supplemental Indenture to Trust Indenture among The Cannabist Company Holdings Inc., The Cannabist Company Holdings (Canada) Inc., and Odyssey Trust Company (March 12, 2025)

Indenture Agreements

Columbia Care Inc.

Pharmaceuticals

2025

Supplemental Indenture No. 2 to 14.750% First Lien Senior Secured Notes Due 2028—Release of Therakos LLC Guarantee

Indenture Agreements

Mallinckrodt

Pharmaceuticals

2025

Supplemental Indenture to 7.875% Senior Notes Due 2034 Among Organon Entities, Dermavant Sciences, and U.S. Bank Trust Company

Indenture Agreements

Organon & Co.

Pharmaceuticals

2025

Supplemental Indenture to 6.750% Senior Secured Notes Due 2034 Among Organon Entities, Dermavant Sciences, and U.S. Bank Trust Company

Indenture Agreements

Organon & Co.

Pharmaceuticals

2025

Fourth Supplemental Indenture to 5.125% Senior Notes Due 2031 by Organon & Co. and Subsidiaries

Indenture Agreements

Organon & Co.

Pharmaceuticals

2025

Fourth Supplemental Indenture to 4.125% Senior Secured Notes Due 2028—Organon & Co. and Subsidiaries

Indenture Agreements

Organon & Co.

Pharmaceuticals

2025

Fourth Supplemental Indenture to 2.875% Senior Secured Notes Due 2028—Organon & Co. and Subsidiaries

Indenture Agreements

Organon & Co.

Pharmaceuticals

2025

Third Supplemental Indenture to 5.125% Senior Notes Due 2031—Alydia Health, Inc., Organon & Co., Organon Foreign Debt Co-Issuer B.V., and U.S. Bank National Association

Indenture Agreements

Organon & Co.

Pharmaceuticals

2025

Third Supplemental Indenture among Alydia Health, Inc., Organon & Co., Organon Foreign Debt Co-Issuer B.V., and U.S. Bank National Association (July 30, 2021)

Indenture Agreements

Organon & Co.

Pharmaceuticals

2025

Third Supplemental Indenture to 2.875% Senior Secured Notes Due 2028 – Alydia Health, Inc., Organon & Co., Organon Foreign Debt Co-Issuer B.V., and U.S. Bank National Association

Indenture Agreements

Organon & Co.

Pharmaceuticals

2025

Johnson & Johnson Company Order for Issuance of Series Notes under Indenture (2025)

Indenture Agreements

Johnson & Johnson

Pharmaceuticals

2025

Eli Lilly and Company Officers’ Certificate Establishing Six Series of Notes under 1991 Indenture

Indenture Agreements

Lilly (Eli) & Co.

Pharmaceuticals

2025

First Supplemental Indenture to 1.75% Convertible Senior Notes Due 2027 between Revance Therapeutics, Inc. and U.S. Bank Trust Company, N.A.

Indenture Agreements

Revance Therapeutics, Inc.

Pharmaceuticals

2025

Supplemental Indenture to Debenture Indenture between CLS Holdings USA, Inc. and Odyssey Trust Company (December 27, 2024)

Indenture Agreements

CLS Holdings USA, Inc.

Pharmaceuticals

2024

Supplemental Indenture No. 7 to Indenture for €350,000,000 5.375% Senior Notes due 2032 among Perrigo Finance Unlimited Company, Perrigo Company plc, Subsidiary Guarantors, and...

Indenture Agreements

Perrigo

Pharmaceuticals

2024

Supplemental Indenture No. 6 to Indenture Dated December 2, 2014 for $715,000,000 6.125% Senior Notes due 2032 among Perrigo Finance Unlimited Company, Perrigo Company plc,...

Indenture Agreements

Perrigo

Pharmaceuticals

2024

Indenture for 3.125% Exchangeable Senior Notes due 2030 among Jazz Investments I Limited, Jazz Pharmaceuticals plc, and U.S. Bank Trust Company

Indenture Agreements

Jazz Pharmaceuticals plc

Pharmaceuticals

2024

Eli Lilly and Company Officers’ Certificate Establishing Series of Notes under 1991 Indenture

Indenture Agreements

Lilly (Eli) & Co.

Pharmaceuticals

2024

ANI Pharmaceuticals, Inc. and U.S. Bank Trust Company, N.A. Indenture for 2.25% Convertible Senior Notes due 2029

Indenture Agreements

ANI Pharma Inc

Pharmaceuticals

2024

Supplemental Indenture No. 1 to 14.750% First Lien Senior Secured Notes Due 2028—Release of Subsidiary Guarantors (Mallinckrodt International Finance S.A., Mallinckrodt CB LLC,...

Indenture Agreements

Mallinckrodt

Pharmaceuticals

2024

Third Supplemental Indenture to Indenture Dated September 2, 2020 among Royalty Pharma plc, Royalty Pharma Holdings Ltd, and Wilmington Trust, National Association (5.150% Senior...

Indenture Agreements

Royalty Pharma plc

Pharmaceuticals

2024

Indenture Agreement among MSD Netherlands Capital B.V., Merck & Co., Inc., and U.S. Bank Trust National Association (May 30, 2024)

Indenture Agreements

Merck

Pharmaceuticals

2024

Indenture for 2.125% Convertible Senior Notes due 2029 between Pacira BioSciences, Inc. and Computershare Trust Company

Indenture Agreements

Pacira Pharmaceuticals, Inc.

Pharmaceuticals

2024

Sixth Supplemental Indenture to Trust Indenture between The Cannabist Company Holdings Inc. and Odyssey Trust Company (September 20, 2023)

Indenture Agreements

Columbia Care Inc.

Pharmaceuticals

2024

Seventh Supplemental Indenture for 9.00% Senior Secured Convertible Notes Due 2027 between The Cannabist Company Holdings Inc. and Odyssey Trust Company

Indenture Agreements

Columbia Care Inc.

Pharmaceuticals

2024

Fifteenth Supplemental Indenture to Indenture Dated June 1, 1993 between Bristol-Myers Squibb Company and The Bank of New York Mellon as Trustee

Indenture Agreements

Bristol-Myers Squibb

Pharmaceuticals

2024

Eli Lilly and Company Officers’ Certificate Establishing Series of Notes under 1991 Indenture

Indenture Agreements

Lilly (Eli) & Co.

Pharmaceuticals

2024

Supplemental Indenture to Convertible Debenture Indenture between CLS Holdings USA, Inc. and Odyssey Trust Company (December 28, 2023)

Indenture Agreements

CLS Holdings USA, Inc.

Pharmaceuticals

2024

Fourteenth Supplemental Indenture to Indenture Dated June 1, 1993 Between Bristol-Myers Squibb Company and The Bank of New York Mellon

Indenture Agreements

Bristol-Myers Squibb

Pharmaceuticals

2023

First Supplemental Indenture to 4.75% Convertible Senior Subordinated Notes Due 2024 between Paratek Pharmaceuticals, Inc. and U.S. Bank Trust Company, N.A.

Indenture Agreements

Paratek Pharmaceuticals, Inc.

Pharmaceuticals

2023

Indenture Agreement for 2.00% Convertible Senior Notes due 2029 between Amphastar Pharmaceuticals, Inc. and U.S. Bank Trust Company, N.A.

Indenture Agreements

Amphastar Pharma

Pharmaceuticals

2023

Indenture Agreement between Canopy Growth Corporation and Odyssey Trust Company dated July 14, 2023

Indenture Agreements

Canopy Growth Corp

Pharmaceuticals

2023

Category

Industry

Companies

Contracts

Indenture Agreements in the Pharmaceuticals Industry